Royal Bank of Canada
CYT

Royal Bank of Canada’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Royal Bank of Canada’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,357
Closed -$16K – 7820
2023
Q4 		$16K Buy
+5,357
New +$16.2K ﹤0.01% 6385
2023
Q3 		– Sell
-888
Closed -$2K – 7810
2023
Q2 		$2K Buy
888
+885
+29,500% +$1.85K ﹤0.01% 6932
2023
Q1 		$0 Hold
3
– – ﹤0.01% 7650
2022
Q4 		$0 Buy
+3
New +$5 ﹤0.01% 7925
2022
Q2 		– Sell
-1,147
Closed -$4K – 7870
2022
Q1 		$4K Sell
1,147
-1,054
-48% -$6K ﹤0.01% 7351
2021
Q4 		$25K Buy
2,201
+1,022
+87% +$15.6K ﹤0.01% 6704
2021
Q3 		$20K Buy
1,179
+884
+300% +$16.5K ﹤0.01% 6716
2021
Q2 		$6K Buy
+295
New +$5.53K ﹤0.01% 7045

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Royal Bank of Canada's CYT Position: Q1 2024 in Review

Royal Bank of Canada sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 5,357 shares — an estimated $16K sold.

Royal Bank of Canada first reported a position in CYT in Q2 2021 and held it in 8 quarters. The position peaked at $25K in Q4 2021. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Royal Bank of Canada reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 5,357 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $16K.
  • Royal Bank of Canada first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
  • Royal Bank of Canada's Cyteir Therapeutics, Inc. Common Stock position peaked at $25K in Q4 2021.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Royal Bank of Canada's 13F filing for Q1 2024, filed 15 May 2024.